Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Immunotherapy with Opdivo Approved for Advanced Esophageal Cancer

August 2020 – Immunotherapy

In June 2020, the FDA approved a new indication for the immunotherapy Opdivo (nivolumab; from Bristol Myers Squibb), a PD-1 inhibitor, for the treatment of patients with unresectable (cannot be removed by surgery) advanced, recurrent, or metastatic (spreading) esophageal squamous-cell carcinoma after the use of chemotherapy. Esophageal squamous-cell carcinoma is among the most common types of esophageal cancer.

Opdivo has been previously approved by the FDA, alone or in combination with other therapies, for the treatment of many solid tumors, including lung, colorectal, liver, melanoma, urothelial, and head and neck cancers, as well as for classical Hodgkin lymphoma. This is the first FDA approval for this immunotherapy for patients with esophageal cancer.

The FDA approved this indication based on the ATTRACTION-3 study, a randomized clinical trial that included 419 patients with unresectable advanced, recurrent, or metastatic esophageal squamous-cell carcinoma. All patients had disease that did not respond to at least 1 chemotherapy regimen. Patients were divided into 2 groups; one group received

Opdivo and the other group received chemotherapy.

The overall survival was significantly better with Opdivo than with chemotherapy. The average overall survival was 10.9 months with Opdivo compared with 8.4 months with chemotherapy. The survival benefit was reported regardless of whether the tumor involved any PD-L1 expression or not.

The average duration of the response to therapy was almost twice as long with Opdivo, at 6.9 months, compared with only 3.9 months with chemotherapy.

The most common side effects in patients receiving nivolumab in this study were rash, decreased appetite, diarrhea, constipation, musculoskeletal pain, upper respiratory tract infection, cough, pyrexia, pneumonia, anemia, fatigue, pruritus, nausea, and hypothyroidism.

Recommended For You